Intervention not reported
True negatives (participants without tuberculosis disease) · of people with HIV‐negative or unknown HIV status who are considered eligible for systematic screening for tuberculosis disease. Role of…
1 finding from 1 review
no estimate extracted
871 participants
Low
Intervention not reported
Proportion of people with COPD diagnoses confirmed with spirometry · health professionals managing COPD
1 finding from 1 review
no estimate extracted
4 participants
Very low
Intervention not reported
Proportion of patients with COPD prescribed respiratory medication consistent with recommended guidelines · health professionals managing COPD
1 finding from 1 review
Intervention not reported
Proportion of patients with COPD vaccinated against influenza/pneumococcal infections · health professionals managing COPD
1 finding from 1 review
Intervention not reported
HRQoL · health professionals managing COPD
1 finding from 1 review
Intervention not reported
Frequency of COPD exacerbations · health professionals managing COPD
1 finding from 1 review
no estimate extracted
10 participants
Low
Intervention not reported
Patient satisfaction with health care · health professionals managing COPD
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review
All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Length of hospital stay · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Quality of life  · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Change in arterial partial pressure of oxygen · stable COPD
2 findings from 1 review